An implantable acellular polymeric scaffold device functionalized with aggrecan is provided. Also provided are methods of fabricating a polymeric scaffold device, including methods of fabricating the scaffold device via 3D printing. Methods of treating a cartilage defect in a subject in need thereof comprise application of the disclosed scaffold device in combination with microfracture procedures. A specialized lid for a centrifugation well plate is also provided.

The present invention provides a valve material having synergistic anti-coagulation and anti-calcification functions and a preparation method therefor. The preparation method comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material; immersing the treated valve material in a blocking solution containing an amine compound for 0.5-6 h, thereby blocking the remaining aldehyde groups after glutaraldehyde cross-linking; then placing the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and performing cross-linking treatment for 6-24 h at 4° C.-37° C.; and finally washing and obtaining the valve material, and storing the valve material in a mixed solvent of glutaraldehyde or isopropyl alcohol/glycerol. The method can effectively solve the problem of calcification and thrombosis caused by residual aldehyde groups in a valve material prepared by the existing method. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

The present disclosure relates to a bio-material composition comprising a dry potassium phosphate based mixture omprising: MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, calcium sodium phosphosilicate, and an antibiotic, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry otassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, and wherein the proteoglycans act as active regulators of collagen fibrillogenesis to thereby structure tissue of a patient by organizing a bone extracellular matrix.

A trigger mechanism that can be used in AR-pattern firearms has a hammer, a trigger member, a disconnector, a locking member, and a “three position” safety selector having safe, standard semi-automatic, and forced reset semi-automatic positions. In the standard semi-automatic position, rearward movement of the bolt carrier causes rearward pivoting of the hammer such that the disconnector hook catches the hammer hook, at which time a user must manually release the trigger member to free the hammer from the disconnector to permit the hammer and trigger member to pivot to the set positions so that the user can pull the trigger member to fire the firearm. In the forced reset semi-automatic position, rearward movement of the bolt carrier causes rearward pivoting of the hammer causing the trigger member to be forced to the set position, the safety selector preventing the disconnector hook from catching the hammer hook, and thereafter when the bolt carrier reaches the substantially in-battery position the user can pull the trigger member to fire the firearm without manually releasing the trigger member. The locking member is pivotable between a first position at which the locking member mechanically blocks the trigger member from moving to the released position and a second position at which the locking member does not mechanically block the trigger member allowing the trigger member to be moved to the released position. The locking member is spring biased toward the first position and moved against the spring bias to the second position by contact from the bolt carrier during forward movement of the bolt carrier as the bolt carrier reaches a substantially in-battery position.

An inducer is directed to the induction of in situ regeneration in regenerative medicine. The inducer including an extracellular matrix and/or a bone morphogenetic protein, can induce the regeneration of bone and soft tissues surrounding the bone such as muscle, blood vessel and skin at the residual tissues where trauma occurs. The amount of regenerated tissue is associated with the dose of the implanted inducer.

Provided is a cardiovascular implant based on in-situ regulation of immune response and a method for making the same, belonging to the technical field of biomedicine. The cardiovascular implant includes a cardiovascular implant body and H4000-CD25/dcas9 sustained-release nanoparticles modified on the cardiovascular implant body; the H4000-CD25/dcas9 sustained-release nanoparticles include an H4000 plasmid nanocarrier (Engreen), an anti-CD25 antibody, and a dcas9 plasmid sequence; a method for preparing the cardiovascular implant includes: constructing a cardiovascular implant body, preparing an H4000-CD25 nanotransfection vector, preparing H4000-CD25/dcas9 sustained-release nanoparticles, and conjugating the H4000-CD25/dcas9 sustained-release nanoparticles on the cardiovascular implant body. The present disclosure aims to construct a cardiovascular implant modified with the H4000-CD25/dcas9 sustained-release nanoparticles, which may induce nerve fiber ingrowth into engineered blood vessels; with the regulation ability of Treg cells on immune response, antithrombotic function of the cardiovascular implant is improved and in-situ regeneration of the cardiovascular implant is promoted.

The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.

This document relates to compositions containing one or more erythropoietin (EPO) polypeptides. For example, this document provides thermoresponsive compositions containing one or more EPO polypeptides and methods for using such thermoresponsive compositions as a delivery system to deliver one or more EPO polypeptides to desired tissue (e.g., to treat a nerve injury and/or a wound). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a nerve injury to treat the nerve injury (e.g., to promote wound healing). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a wound to treat the wound (e.g., to promote wound healing).

Porous implantable devices for housing one or more therapeutic agents are disclosed herein. The implantable devices include a porous outer wall defining an interia or void. The interior void houses a carrier material carrying a first therapeutic agent. The implantable devices are made by patterning at least a portion of a polymerizable substrate into a polymerized three-dimensional porous outer wall surrounding an interior void. This can be achieved by two-photon polymerization techniques. A first therapeutic agent is then added to the interior void, which is then sealed. Methods of treating diseases using the implantable devices are disclosed herein. The methods include implanting the implantable device at a target area and locally releasing a therapeutically effective dosage of a first therapeutic agent from the interior void. The implantable devices can also be used in methods of screening potentially therapeutic agents for desired biological responses.

The present invention relates to a wound covering with prominent biocompatible and accelerated wound-healing and its preparation method thereof. The wound covering comprises a film prepared from collagen and Dopa-containing protein—mussel adhesive protein, which is immobilized on collagen by chemical cross-linking, thus enhances the stability of protein structure and maintains the activity of collagen and mussel adhesive protein. The wound covering has excellent mechanical strength and can be trimmed into any shape; it accelerates tissue epithelisation and promotes wound healing with good biocompatibility, non-adhesive to the wound and no further wound damages.